Development and validation of prognostic survival models in newly diagnosed Parkinson’s disease
| dc.contributor.author | Macleod, Angus D | |
| dc.contributor.author | Dalen, Ingvild | |
| dc.contributor.author | Tysnes, Ole-Bjørn | |
| dc.contributor.author | Larsen, Jan Petter | |
| dc.contributor.author | Counsell, Carl E | |
| dc.contributor.institution | University of Aberdeen.Aberdeen Centre for Health Data Science | en |
| dc.contributor.institution | University of Aberdeen.Grampian Data Safe Haven (DaSH) | en |
| dc.contributor.institution | University of Aberdeen.Chronic Disease Research Group | en |
| dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
| dc.date.accessioned | 2018-02-01T14:28:07Z | |
| dc.date.available | 2018-02-01T14:28:07Z | |
| dc.date.issued | 2018-01-31 | |
| dc.description | Acknowledgments We would like to thank study participants, study personnel, and study funders. Funding agencies: The Parkinsonism Incidence in North-East Scotland (PINE) study was supported by Parkinson's UK (Grants G-0502, G-0914, G-1302), the Scottish Chief Scientist Office (CAF 12/05), the British Medical Association (BMA) Doris Hillier award, RS Macdonald Trust, the Bupa Foundation, National Health Service (NHS) Grampian endowments, NHS R&D, and SPRING. The ParkWest study was supported by the Research Council of Norway (Grant 177966), the Western Norway Regional Health Authority (Grants 911218 and 911949), and the Norwegian Parkinson's Disease Association. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 9 | |
| dc.format.extent | 636524 | |
| dc.identifier | 107331495 | |
| dc.identifier | beff90f6-ee3c-45be-9244-78e9bb6235c8 | |
| dc.identifier | 28976022 | |
| dc.identifier | 28976022 | |
| dc.identifier | 85040677583 | |
| dc.identifier.citation | Macleod, A D, Dalen, I, Tysnes, O-B, Larsen, J P & Counsell, C E 2018, 'Development and validation of prognostic survival models in newly diagnosed Parkinson’s disease', Movement Disorders, vol. 33, no. 1, pp. 108-116. https://doi.org/10.1002/mds.27177 | en |
| dc.identifier.doi | 10.1002/mds.27177 | |
| dc.identifier.iss | 1 | en |
| dc.identifier.issn | 0885-3185 | |
| dc.identifier.other | ORCID: /0000-0001-6622-7839/work/164505583 | |
| dc.identifier.other | ORCID: /0000-0002-6284-4239/work/191926805 | |
| dc.identifier.uri | http://hdl.handle.net/2164/9977 | |
| dc.identifier.vol | 33 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Movement Disorders | en |
| dc.subject | dependency | en |
| dc.subject | Parkinson's disease | en |
| dc.subject | prognosis | en |
| dc.subject | mortality | en |
| dc.subject | RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry | en |
| dc.subject | Parkinson's UK | en |
| dc.subject | G-0502 | en |
| dc.subject | G-0914 | en |
| dc.subject | G-1302 | en |
| dc.subject | Chief Scientist Office (CSO) | en |
| dc.subject | CAF 12/05 | en |
| dc.subject | Supplementary Data | en |
| dc.subject.lcc | RC0321 | en |
| dc.title | Development and validation of prognostic survival models in newly diagnosed Parkinson’s disease | en |
| dc.type | Journal article | en |
